https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-01 / Expert Opin Biol Ther 2009 Mar;9(3):331-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-01 / Expert Opin Biol Ther 2009 Mar;9(3):331-92009-03-01 00:00:002019-02-15 09:23:39Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-26 / Gene Ther. 2009 Jun;16(6):796-804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-26 / Gene Ther. 2009 Jun;16(6):796-8042009-02-26 00:00:002009-02-26 00:00:00Genetically engineered Newcastle disease virus for malignant melanoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-25 / Strahlenther Onkol 2009 Feb;185(2):120-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-25 / Strahlenther Onkol 2009 Feb;185(2):120-62009-02-25 00:00:002019-02-15 09:17:37Strong synergy of heat and modulated electromagnetic field in tumor cell killing
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-19 / Cancer Immunol. Immunother. 2009 Oct;58(10):1669-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-19 / Cancer Immunol. Immunother. 2009 Oct;58(10):1669-772009-02-19 00:00:002019-02-15 08:32:26Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-17 / Cancer Immunol. Immunother. 2009 Oct;58(10):1587-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-17 / Cancer Immunol. Immunother. 2009 Oct;58(10):1587-972009-02-17 00:00:002019-02-15 09:16:51Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-15 / Int. J. Cancer 2009 Feb;124(4):877-88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-15 / Int. J. Cancer 2009 Feb;124(4):877-882009-02-15 00:00:002019-02-15 08:38:02Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-13 / Neurosurg Rev 2009 Jul;32(3):265-73; discussion 273
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-13 / Neurosurg Rev 2009 Jul;32(3):265-73; discussion 2732009-02-13 00:00:002019-02-15 08:59:41Dendritic-cell- and peptide-based vaccination strategies for glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-10 / Mol. Ther. 2009 Apr;17(4):697-706
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-10 / Mol. Ther. 2009 Apr;17(4):697-7062009-02-10 00:00:002019-02-15 09:21:52Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-08 / Clin. Immunol. 2009 Apr;131(1):1-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-08 / Clin. Immunol. 2009 Apr;131(1):1-102009-02-08 00:00:002019-02-15 09:23:57FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-05 / Vaccine 2009 May;27(25-26):3401-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-05 / Vaccine 2009 May;27(25-26):3401-42009-02-05 00:00:002019-02-15 08:44:21Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
